Cochrane · systematic review · CD005068
Interventions for pityriasis rosea
Contreras‐Ruiz, J, Peternel, S, Jiménez Gutiérrez, C, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
24
No studies
12
Included studies
NR
No studies 12 · 33.3%Ungraded 0 · 0%Very low 0 · 0%Low 9 · 25%Moderate 15 · 41.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Clarithromycin compared to placebo for pityriasis rosea
Population: pityriasis rosea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant Clarithromycin vs placebo | no estimate extracted | NR | No studies |
Serious adverse events, i.e. serious enough to require withdrawal of the treatment Clarithromycin vs placebo | no estimate extracted | 1 study · 60 participants | Moderate Downgraded: imprecision |
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant Clarithromycin vs placebo | RR 0.84 [0.47, 1.52] | 1 study · 28 participants | Moderate Downgraded: imprecision |
Reduction in itch score within 2 weeks, as rated by the participant Clarithromycin vs placebo | no estimate extracted | NR | No studies |
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner Clarithromycin vs placebo | RR 1.13 [0.89, 1.44] | 1 study · 60 participants | Moderate Downgraded: imprecision |
Minor participant‐reported adverse events not requiring withdrawal of the treatment Clarithromycin vs placebo | no estimate extracted | NR | No studies |
Erythromycin compared to placebo for pityriasis rosea
Population: pityriasis rosea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant Erythromycin vs placebo | no estimate extracted | NR | No studies |
Serious adverse events, i.e. serious enough to require withdrawal of the treatment Erythromycin vs placebo | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant Erythromycin vs placebo | no estimate extracted | NR | No studies |
Reduction in itch score within 2 weeks as rated by the participant Erythromycin vs placebo | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
The proportion of participants with good or excellent rash improvement within 2 weeks as rated by a medical practitioner Erythromycin vs placebo | RR 4.02 [0.28, 56.61] | 2 studies · 86 participants | Low Downgraded: imprecision, inconsistency |
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Gastrointestinal upset. Erythromycin vs placebo | RR 2 [0.2, 20.04] | 1 study · 34 participants | Moderate Downgraded: imprecision |
Azithromycin compared to placebo or vitamins for pityriasis rosea
Population: pityriasis rosea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant Azithromycin vs placebo or vitamins | no estimate extracted | NR | No studies |
Serious adverse events, i.e. serious enough to require withdrawal of the treatment Azithromycin vs placebo or vitamins | no estimate extracted | 2 studies · 119 participants | Moderate Downgraded: imprecision |
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant Azithromycin vs placebo or vitamins | RR 0.83 [0.28, 2.48] | 1 study · 70 participants | Moderate Downgraded: imprecision |
Reduction in itch score within 2 weeks, as rated by the participant Azithromycin vs placebo or vitamins | no estimate extracted | 1 study · 70 participants | Moderate Downgraded: imprecision |
The proportion of participants with good or excellent rash improvement within 2 weeks as rated by a medical practitioner. Azithromycin vs placebo or vitamins | RR 1.02 [0.52, 2] | 2 studies · 119 participants | Low Downgraded: risk of bias, imprecision |
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Mild abdominal pain. Azithromycin vs placebo or vitamins | RR 5.82 [0.72, 47.1] | 2 studies · 119 participants | Moderate Downgraded: imprecision |
Acyclovir compared to placebo, vitamins, or no treatment for pityriasis rosea
Population: pityriasis rosea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant Acyclovir vs placebo, vitamins, or no treatment | no estimate extracted | NR | No studies |
Serious adverse events, i.e. serious enough to require withdrawal of the treatment Acyclovir vs placebo, vitamins, or no treatment | no estimate extracted | 3 studies · 141 participants | Moderate Downgraded: imprecision |
Proportion of participants with resolution of itch within 2 weeks, as rated by the participant Acyclovir vs placebo, vitamins, or no treatment | RR 0.34 [0.12, 0.94] | 1 study · 21 participants | Moderate Downgraded: imprecision |
Reduction in itch score within 2 weeks, as rated by the participant Acyclovir vs placebo, vitamins, or no treatment | no estimate extracted | NR | No studies |
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner Acyclovir vs placebo, vitamins, or no treatment | RR 2.45 [1.33, 4.53] | 3 studies · 141 participants | Moderate Downgraded: risk of bias |
Minor participant‐reported adverse events not requiring withdrawal of the treatment Acyclovir vs placebo, vitamins, or no treatment | RR 0.31 [0.01, 7.02] | 3 studies · 141 participants | Moderate Downgraded: imprecision |
Acyclovir + calamine + cetirizine compared to calamine + cetirizine for pityriasis rosea
Population: pityriasis rosea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant Acyclovir + calamine + cetirizine vs calamine + cetirizine | no estimate extracted | NR | No studies |
Serious adverse events, i.e. serious enough to require withdrawal of the treatment Acyclovir + calamine + cetirizine vs calamine + cetirizine | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant Acyclovir + calamine + cetirizine vs calamine + cetirizine | RR 4.5 [1.22, 16.62] | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Reduction in itch score within 2 weeks, as rated by the participant Acyclovir + calamine + cetirizine vs calamine + cetirizine | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner Acyclovir + calamine + cetirizine vs calamine + cetirizine | no estimate extracted | NR | No studies |
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Headache. Acyclovir + calamine + cetirizine vs calamine + cetirizine | RR 7 [0.4, 122.44] | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Acyclovir compared to erythromycin for pityriasis rosea
Population: pityriasis rosea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant Acyclovir vs erythromycin | no estimate extracted | NR | No studies |
Serious adverse events, i.e. serious enough to require withdrawal of the treatment Acyclovir vs erythromycin | no estimate extracted | 1 study · 30 participants | Moderate Downgraded: imprecision |
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant Acyclovir vs erythromycin | RR 13.22 [0.91, 192.02] | 1 study · 14 participants | Low Downgraded: risk of bias, imprecision |
Reduction in itch score within 2 weeks, as rated by the participant Acyclovir vs erythromycin | no estimate extracted | NR | No studies |
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner Acyclovir vs erythromycin | no estimate extracted | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |
Minor participant‐reported adverse events not requiring withdrawal of the treatment Acyclovir vs erythromycin | no estimate extracted | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |